Text of Senate Amendment 6601

On 2026-07-13, Senator Rick Scott (R-FL) delivered a floor speech titled "Text Of Senate Amendment 6601" in the Senate.

Text of Senate Amendment 6601

Congressional Record, Volume 172 Issue 113 (Monday, July 13, 2026) [Congressional Record Volume 172, Number 113 (Monday, July 13, 2026)] [Senate] [Pages S3794-S3795] From the Congressional Record Online through the Government Publishing Office [ www.gpo.gov ] SA 6601. Mr. SCOTT of Florida submitted an amendment intended to be proposed by him to the bill S. 4784, to authorize appropriations for fiscal year [[Page S3795]] 2027 for military activities of the Department of Defense, for military construction, and for defense activities of the Department of Energy, to prescribe military personnel strengths for such fiscal year, and for other purposes; which was ordered to lie on the table; as follows: At the appropriate place in subtitle G of title X, insert the following: SEC. __. CLEAR LABELS ACT. (a) Require Drug Labeling to Include Original Manufacturer and Supply Chain Information.--Section 502(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352(b)) is amended-- (1) by striking ``containing (1) the name and place of business of the manufacturer, packer, or distributor'' and inserting the following: ``containing-- ``(A) the name, place of business, and unique facility identifier of the manufacturer, packer, or distributor or a link, barcode, QR code, or other means to access a searchable electronic portal containing such information''; (2) in clause (A) (as so designated), by striking ``(2) an accurate'' and inserting the following: ``(B) an accurate''; (3) in clause (B) (as so designated), by striking ``count: Provided, That under clause (2) of this paragraph reasonable variations'' and inserting ``count, provided that under this clause, reasonable variations''; (4) by striking ``(b) If in a package form'' and inserting the following: ``(b)(1) If it is a finished drug product in a package form''; and (5) by adding at the end the following: ``(2) If it is an active pharmaceutical ingredient, unless any accompanying label and certificate of analysis contains the name, place of business, and unique facility identifier of the original manufacturer. ``(3)(A) If it is a finished drug product, unless its labeling contains the name, place of business, and unique facility identifier of-- ``(i) the original manufacturer of each active pharmaceutical ingredient; ``(ii) the original manufacturer of the finished drug product; and ``(iii) the packer or distributor, if any, or a link, barcode, QR code, or other means to access a searchable electronic portal containing such information. ``(B) In the case of a finished drug product for which there are multiple potential different manufacturers of the active pharmaceutical ingredient, the requirements of this subparagraph shall be satisfied if all such manufacturers of active pharmaceutical ingredients for the drug product are identified in the labeling or the searchable electronic portal. ``(4) A manufacturer, packer, or distributor required to furnish information under paragraphs (1), (2), and (3), in addition to making such information available electronically, as applicable, shall make such information available through a package insert, or in paper copy to any individual who requests such a copy. ``(5) For purposes of this subsection, the term `original manufacturer', means the single last establishment to conduct substantial manufacturing activities prior to introduction of the active pharmaceutical ingredient or finished drug product into interstate commerce. ``(6) The Secretary shall issue regulations to implement subparagraphs (2) and (3) and may provide for reasonable variations in the implementation of, or an alternative placement for, the labeling requirements under such subparagraphs, including by electronic means. Such regulations shall take effect on a date determined by the Secretary and not earlier than 1 year after the date of publication of the final regulations, and shall apply with respect to drugs manufactured on or after the effective date of such regulations.''. (b) Exemption From Customs Country of Origin Marking Requirement.-- Section 304 of the Tariff Act of 1930 (19 U.S.C. 1304) is amended by adding at the end the following: ``(m) Marking of Certain Finished Drug Products.--The marking requirements of subsections (a) and (b) shall not apply to articles that are finished drug products and are marked in accordance with the requirements of section 502(b)(2) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352(b)(2)).''. ______